Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the creation of Alopecia Areata Uniform Protocols by the National Alopecia Areata Foundation to standardize clinical trials for alopecia areata treatments and reports no new results.

A new acne cream effectively reduced acne in trials and awaits FDA approval.

This study found that FDA-approved low-level light/laser therapy devices significantly increased hair density in individuals with pattern hair loss compared to sham devices.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This review concluded that FDA-cleared low-level laser therapy devices are safe and effective for patients with male and female pattern hair loss who do not respond to or tolerate standard treatments.

This review discusses the challenges in selecting optical parameters for photobiomodulation studies on hair regrowth and wound healing, reporting no new clinical results and recommending more rigorous, standardized research approaches.

This review summarizes existing data on the efficacy and safety of topical minoxidil for androgenetic alopecia but reports no new clinical findings; the authors emphasize the need for realistic evaluation of its potential.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This article highlights online claims about exosomes as a promising hair loss treatment but reports no clinical results; it calls attention to the need for critical evaluation and further research.

This review discusses cases and research on paradoxical hair growth after laser hair removal and explores laser and light therapies for treating alopecia, but reports no new results.

This article reviews the limitations in current research on photobiomodulation for hair regrowth and suggests that optimal wavelengths and dosing have not yet been identified, noting that recommending these devices may be premature.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

In this study, finasteride exposure in human prostatic cell lines did not affect cell proliferation but significantly reduced MMP activity and increased TIMP expression, potentially inhibiting tumor cell invasion and metastasis.

This review explores the current treatments for different types of alopecia, emphasizing the need for well-designed clinical trials and highlighting that most therapies are used off-label, as only androgenetic alopecia has FDA-approved drugs.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

This article discusses the FDA approval history of finasteride and does not report new research findings.

This narrative review concludes that long-term randomized controlled trials are needed to establish clear guidelines for testosterone therapy in women, given the lack of FDA-approved formulations and the variable quality of current treatments.

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

In this literature review, exosomes show promise in cosmetic dermatology for skin rejuvenation and hair restoration; however, challenges like inconsistent isolation methods and lack of FDA approval necessitate further clinical trials to ensure long-term safety and efficacy.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This review discusses considerations for choosing antihypertensive agents in children, including factors like side effects and FDA approval status, and reports no new clinical results.

This study of photobiomodulation therapy devices for androgenetic alopecia found variable improvements in hair grade across different skin types and devices, suggesting a need for larger, more comprehensive trials.

The safety of the hair loss drug finasteride is unclear due to inadequate reporting in clinical trials.

The FDA approved a new Pfizer drug for hair loss in teens.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.

This study identified five FDA-approved drugs—cepharantine, clofazimine, metergoline, imatinib, and efloxate—as potential candidates for repurposing to interfere with viral entry in COVID-19 treatment.

This article examines advancements in understanding and managing androgenic alopecia (male pattern baldness), discussing genetic and psychological factors, diagnostic methods, classifications, and various treatment options, including traditional and emerging therapies, to aid healthcare professionals in making informed treatment decisions.